SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today the expansion of ongoing clinical trials using Rexin-G(TM) in the United States to include breast cancer and all types of sarcomas that have failed standard chemotherapy. Following on the heels of their landmark clinical trials in the United States and abroad, the US FDA granted Orphan Drug Status for Rexin-G.

NEW YORK, N.Y. -- Eularis is announcing the release of an update to its report "Pharmaceutical eMarketing: Building Brands, Relationships & Business Through Web...

SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Rexin-G, its lead product in development for metastatic cancer, has been highlighted in a...

KENILWORTH, N.J. -- 3C Company, Inc., a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announces today the release of a new module to its highly successful Clintelligence(R) Business Intelligence Solution.

NEW YORK, N.Y. and LONDON, U.K. -- Eularis today announced the release of a first-ever study on the ROI of named patient programmes (NPP),...

SAN MARINO, Calif. and BOSTON, Mass. -- Epeius Biotechnologies Corporation today announced that Dr. Frederick L. Hall, President and CEO of Epeius Biotechnologies Inc., has accepted an invitation to give the lead keynote address on "The Advent of Pathotropic Medicine for Cancer" at the Global Pharma R&D Summit 2007 to be held in Boston MA. On October 22, 2007 at 8:00 a.m., Dr. Hall will present the scientific principles, the clinical validation, and global development status.

WASHINGTON, D.C. -- Belvidere Pharmacy is the first pharmacy in the state of New Jersey to earn the Pharmacy Compounding Accreditation Board's Seal of Accreditation - a new system of standards created by some of the leading organizations in pharmacy. The accreditation demonstrates that Belvidere Pharmacy meets the highest quality and safety standards in its profession.

KENILWORTH, N.J. -- 3C Company, Inc. (www.3cpharma.com), a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announced today that it has aligned with yet another Global Pharmaceutical Firm to implement Clintelligence - 3C Company's Business Intelligence Solution for strategic and tactical oversight of their Research and Development portfolio.

SAN MARINO, Calif. -- Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast...

NEW YORK, N.Y. and LONDON, England -- Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on meeting the challenges of measuring ROI within the changing dynamics of the pharma industry. On Wednesday 26 March 2008, Dr. Bates will deliver a presentation titled, "Are You Up to the Challenge of Measuring ROI in Changing Dynamics of the Pharma Industry?"